Aeglea Bio Therapeutics Inc logo

AGLE - Aeglea Bio Therapeutics Inc Share Price

$9.06 -0.3  -2.9%

Last Trade - 02/07/20

Sector
Healthcare
Size
Small Cap
Market Cap £323.7m
Enterprise Value £284.4m
Revenue £n/a
Position in Universe 3048th / 6344
Bullish
Bearish
Unlock AGLE Revenue
Momentum
Relative Strength (%)
1m -0.34%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -20.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 6.09 4.63 5.21 3.89 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Aeglea Bio Therapeutics Inc revenues was not reported. Net loss increased 9% to $18.7M. Higher net loss reflects General and administrative - increase of 41% to $3.6M (expense), Interest income decrease of 41% to $300K (income), Stock-based Compensation in SGA increase of 20% to $816K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.59 to -$0.57.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AGLE Revenue Unlock AGLE Revenue

Net Income

AGLE Net Income Unlock AGLE Revenue

Normalised EPS

AGLE Normalised EPS Unlock AGLE Revenue

PE Ratio Range

AGLE PE Ratio Range Unlock AGLE Revenue

Dividend Yield Range

AGLE Dividend Yield Range Unlock AGLE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AGLE EPS Forecasts Unlock AGLE Revenue
Profile Summary

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated December 16, 2013
Public Since April 7, 2016
No. of Shareholders: 24
No. of Employees: 79
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 44,593,764
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AGLE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AGLE
Upcoming Events for AGLE
Frequently Asked Questions for Aeglea Bio Therapeutics Inc
What is the Aeglea Bio Therapeutics Inc share price?

As of 02/07/20, shares in Aeglea Bio Therapeutics Inc are trading at $9.06, giving the company a market capitalisation of £323.7m. This share price information is delayed by 15 minutes.

How has the Aeglea Bio Therapeutics Inc share price performed this year?

Shares in Aeglea Bio Therapeutics Inc are currently trading at $9.06 and the price has moved by 37.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aeglea Bio Therapeutics Inc price has moved by 31.15% over the past year.

What are the analyst and broker recommendations for Aeglea Bio Therapeutics Inc?

Of the analysts with advisory recommendations for Aeglea Bio Therapeutics Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aeglea Bio Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Aeglea Bio Therapeutics Inc next release its financial results?

Aeglea Bio Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Aeglea Bio Therapeutics Inc dividend yield?

Aeglea Bio Therapeutics Inc does not currently pay a dividend.

Does Aeglea Bio Therapeutics Inc pay a dividend?

Aeglea Bio Therapeutics Inc does not currently pay a dividend.

When does Aeglea Bio Therapeutics Inc next pay dividends?

Aeglea Bio Therapeutics Inc does not currently pay a dividend.

How do I buy Aeglea Bio Therapeutics Inc shares?

To buy shares in Aeglea Bio Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aeglea Bio Therapeutics Inc?

Shares in Aeglea Bio Therapeutics Inc are currently trading at $9.06, giving the company a market capitalisation of £323.7m.

Where are Aeglea Bio Therapeutics Inc shares listed? Where are Aeglea Bio Therapeutics Inc shares listed?

Here are the trading details for Aeglea Bio Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: AGLE
What kind of share is Aeglea Bio Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Aeglea Bio Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aeglea Bio Therapeutics Inc share price forecast 2020?

Shares in Aeglea Bio Therapeutics Inc are currently priced at $9.06. At that level they are trading at 85.76% discount to the analyst consensus target price of 0.00.

Analysts covering Aeglea Bio Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.877 for the next financial year.

How can I tell whether the Aeglea Bio Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aeglea Bio Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 22.19%. At the current price of $9.06, shares in Aeglea Bio Therapeutics Inc are trading at 21.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aeglea Bio Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Aeglea Bio Therapeutics Inc.

Who are the key directors of Aeglea Bio Therapeutics Inc?

Aeglea Bio Therapeutics Inc's management team is headed by:

Charles York - CFO
Sandesh Mahatme - IND
Russell Cox - CHM
Armen Shanafelt - IND
Anthony Quinn - PRE
Suzanne Bruhn - IND
Ivana Magovcevic-Liebisch - IND
V. Bryan Lawlis - IND
Leslie Sloan - COO
Ravi Rao - OTH
Michael Hanley - OTH
Who are the major shareholders of Aeglea Bio Therapeutics Inc?

Here are the top five shareholders of Aeglea Bio Therapeutics Inc based on the size of their shareholding:

OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 6.43% (2.87m shares)
Nantahala Capital Management, LLC Hedge Fund
Percentage owned: 6.4% (2.85m shares)
Bain Capital Life Sciences Investors, LLC Investment Advisor
Percentage owned: 6.05% (2.70m shares)
Lilly Ventures Venture Capital
Percentage owned: 5.76% (2.57m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.91% (1.74m shares)
Similar to AGLE
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.